• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

验证数据展示

  • WB analysis using 31840-1-AP (same clone as 31840-1-PBS)

    WB analysis using 31840-1-AP (same clone as 31840-1-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 31840-1-AP (TATDN1 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 31840-1-PBS in a different storage buffer formulation.

TATDN1 Polyclonal antibody, PBS Only

TATDN1 Polyclonal Antibody for WB, Indirect ELISA
Cat No. 31840-1-PBS

产品说明书

宿主/亚型

Rabbit / IgG

种属反应性

human

应用

WB, Indirect ELISA

别名

缓冲液配方:  PBS Only
PBS and Azide
PBS Only
偶联物:  Unconjugated
规格: 

-/ -

点击咨询售前客服

点击咨询售后客服

产品信息

31840-1-PBS targets TATDN1 in WB, Indirect ELISA applications and shows reactivity with human samples.

经测试应用 WB, Indirect ELISA Application Description
经测试反应性 human
免疫原 TATDN1 fusion protein Ag36040 种属同源性预测
宿主/亚型 Rabbit / IgG
抗体类别 Polyclonal
产品类型 Antibody
全称 TatD DNase domain containing 1
别名
观测分子量30 kDa
GenBank蛋白编号BC064964
基因名称 TATDN1
Gene ID (NCBI) 83940
偶联类型 Unconjugated
形式 Liquid
纯化方式Antigen affinity Purification
UNIPROT IDQ6P1N9
储存缓冲液 PBS only , pH 7.3
储存条件Store at -80°C.
The product is shipped with ice packs. Upon receipt, store it immediately at -80°C

背景介绍

Homo sapiens TatD DNase domain containing 1 (TATDN1), a member of the TATD family, is a highly conserved nuclease in both prokaryotes and eukaryotes with depurine/apyrimidine (AP) endonuclease activity, which plays an extremely important role in the genesis and prognosis of malignant tumors such as NSCLC and breast cancer, and is a potential therapeutic target for NSCLC patients who have failed to undergo cisplatin therapy (DDP) in vivo.